The three best-studied peptides for cognitive function are Semax (BDNF upregulation, approved in Russia for cognitive disorders), Selank (GABA modulation with anti-anxiety effects), and Cerebrolysin (porcine-derived neurotrophic mixture used clinically in 40+ countries for stroke and dementia). Each has human clinical data supporting cognitive effects, unlike most compounds sold as "nootropic peptides."
The brain peptide landscape is crowded with hype. Vendor sites list 6-8 compounds with identical "boosts cognition" claims and no evidence grading. This guide ranks 12 peptides by the quality of their evidence, from approved clinical use down to preclinical-only compounds. One widely promoted peptide, Dihexa, had its foundational research paper retracted in 2025 for data manipulation.
| Peptide | Evidence Level | Primary Mechanism | Route | Key Cognitive Effect |
|---|---|---|---|---|
| Semax | Strong (human trials + approval) | BDNF/NGF upregulation | Intranasal | Focus, memory, neuroprotection |
| Selank | Strong (human trials + approval) | GABA modulation, enkephalin | Intranasal | Anxiety-related cognitive impairment |
| Cerebrolysin | Strong (RCTs, meta-analyses) | Neurotrophic factor mixture | IV/IM injection | Dementia, stroke recovery |
| BPC-157 | Moderate (animal studies) | Dopamine/serotonin system repair | SC injection, oral | Neuroprotection, neurotransmitter balance |
| Noopept | Moderate (limited human data) | BDNF/NGF, glutamate modulation | Oral, sublingual | Memory consolidation |
| DSIP | Moderate (human trials) | Delta sleep regulation | SC injection | Sleep-dependent memory consolidation |
| Dihexa | Contested (retracted study) | HGF/c-Met pathway | Oral | Synaptogenesis (evidence compromised) |
| GHK-Cu | Preliminary (preclinical) | Gene expression modulation | Intranasal, SC | Neuroprotection |
| Epitalon | Preliminary (preclinical) | Melatonin/telomerase | SC injection | Circadian rhythm, indirect cognitive |
| PE-22-28 | Preliminary (preclinical) | TREK-1 channel, BDNF | Intranasal | Antidepressant, potential cognitive |
| P21 (Cerebrolysin-derived) | Preliminary (preclinical) | CNTF pathway mimicry | Intranasal | Neurogenesis |
| FGL | Preliminary (preclinical) | NCAM/FGFR pathway | Injection | Synaptic plasticity, memory |
This guide covers mechanisms, dosing protocols, evidence quality, and safety for each compound. For general peptide preparation, see our reconstitution guide and injection guide.
Get your custom peptide protocol:
- Tailored to your body and goals
- Precise dosing and cycle length
- Safe stacking combinations
- Backed by peer-reviewed studies
- Ready in under 2 minutes
How Peptides Enhance Cognitive Function
Cognitive peptides work through four primary mechanisms, often overlapping. Understanding these pathways explains why certain peptides suit certain cognitive goals.
1. Neurotrophin upregulation (BDNF, NGF, CNTF) Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are proteins that support neuron survival, growth, and synaptic plasticity. Higher BDNF correlates with better memory formation and learning speed. Semax, Noopept, and PE-22-28 increase BDNF expression through different receptor pathways.
2. Neurotransmitter modulation (dopamine, serotonin, GABA) Selank modulates GABA-A receptor sensitivity, reducing anxiety that impairs working memory and executive function. BPC-157 influences both dopamine and serotonin turnover, potentially restoring neurotransmitter balance disrupted by stress, substance use, or neurodegeneration.
3. Synaptogenesis and dendritic spine growth New synapse formation is the physical basis of learning. Cerebrolysin provides a cocktail of neurotrophic peptides that promote synaptogenesis. Dihexa was claimed to do this through HGF/c-Met activation, though the key study supporting this claim has been retracted.
4. Neuroprotection and repair Some peptides protect neurons from oxidative stress, excitotoxicity, or inflammatory damage. GHK-Cu modulates expression of genes involved in antioxidant defense. BPC-157 has shown neuroprotective effects in animal models of traumatic brain injury and drug-induced neurotoxicity (Sikiric et al. 2021, PMC8504390).
The most effective cognitive peptides combine multiple mechanisms. Semax, for example, upregulates BDNF while also modulating dopamine and serotonin, providing both structural neuroplasticity and acute neurotransmitter effects.
Tier 1: Strong Evidence (Human Trials or Clinical Approval)
These three peptides have the strongest clinical evidence for cognitive effects. Two are approved medications in Russia. One has been tested in randomized controlled trials across multiple countries.
Semax: The Focus and Memory Peptide
Semax is a synthetic analogue of ACTH(4-10), the fragment of adrenocorticotropic hormone responsible for its nootropic effects without hormonal activity. Developed at the Institute of Molecular Genetics in Moscow, it has been approved in Russia since 1994 for cognitive disorders, stroke recovery, and optic nerve atrophy.
Mechanism: Semax rapidly upregulates BDNF and its receptor trkB in the hippocampus and cortex. A study in rats showed significant BDNF mRNA increases within 30 minutes of intranasal administration, with effects lasting 24 hours (Dolotov et al. 2006, PubMed 16996037). It also modulates dopaminergic and serotonergic transmission, contributing to its pro-focus effects.
Cognitive effects demonstrated: - Improved attention and memory consolidation in clinical studies - Neuroprotection in ischemic stroke (standard treatment protocol in Russia) - Enhanced learning in both healthy subjects and cognitively impaired patients
Dosage: Intranasal spray, 200-600 mcg/day (typically 1-2 drops of 0.1% solution per nostril, 2-3 times daily). Cycles of 10-14 days with equal time off. Effects noticeable within 15-30 minutes of administration due to rapid nasal mucosal absorption.
Best for: Focus, memory formation, mental clarity, stroke recovery support.
For detailed protocols, see the Semax profile page.
Selank: The Anti-Anxiety Cognitive Enhancer
Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, developed at the same Moscow institute as Semax. Approved in Russia as an anxiolytic with nootropic properties, it approaches cognitive enhancement from a different angle: by reducing the anxiety and stress that impair cognitive performance.
Mechanism: Selank modulates GABA-A receptor sensitivity and inhibits the enzyme enkephalinase, which breaks down endogenous enkephalins (natural calming peptides). This increases enkephalin availability without sedation. It also influences serotonin metabolism and IL-6 expression. A clinical trial in patients with generalized anxiety disorder (GAD) showed anxiolytic effects comparable to medazepam (a benzodiazepine) without sedation or cognitive impairment (Zozulya et al. 2008, PubMed 18454096).
Cognitive effects demonstrated: - Improved cognitive performance in anxious patients (by removing anxiety-driven cognitive suppression) - Enhanced memory stability under stress conditions - No tolerance, dependence, or withdrawal effects reported (unlike benzodiazepines)
Dosage: Intranasal spray, 250-500 mcg/day (typically 2-3 drops of 0.15% solution per nostril, 2-3 times daily). Cycles of 14-21 days. Can be stacked with Semax for combined focus and calm.
Best for: Brain fog caused by anxiety, stress-impaired cognition, performance anxiety, test-taking.
For detailed protocols, see the Selank profile page. See also our guide on peptides for anxiety for a broader view of anxiolytic peptides.
Cerebrolysin: The Clinical Neurotrophic Mixture
Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides (less than 10 kDa) and free amino acids. It is not a single peptide but a standardized mixture that mimics the activity of endogenous neurotrophic factors. Approved in over 40 countries (but not the US or UK) for Alzheimer's disease, traumatic brain injury, and stroke.
Mechanism: The peptide mixture contains fragments that mimic BDNF, GDNF, NGF, and CNTF activity. It crosses the blood-brain barrier and promotes neuronal survival, synaptogenesis, and dendritic branching. Unlike single-peptide approaches, Cerebrolysin provides multiple neurotrophic signals simultaneously.
Clinical evidence: A meta-analysis of Cerebrolysin in Alzheimer's disease (including 6 RCTs, 784 patients) found significant improvement in clinical global impression scores compared to placebo (Plosker & Gauthier 2009, PubMed 25832905). Individual trials showed improvements in ADAS-cog scores (the standard cognitive assessment for Alzheimer's trials).
Dosage: 10-30 mL IV infusion or IM injection daily for 20-28 days. This is a clinical-grade medication requiring medical supervision. Some practitioners use lower doses (5-10 mL IM) in wellness protocols, though this represents off-label use outside approved indications.
Limitations: Requires injection (IV preferred for larger doses), not available as a consumer peptide in most markets, high cost, porcine origin raises concerns for some users. Not FDA-approved, limiting access in the US.
Best for: Age-related cognitive decline, post-stroke recovery, Alzheimer's disease (as adjunct to standard care, under medical supervision).
Tier 2: Moderate Evidence (Animal Studies or Limited Human Data)
These peptides have supporting animal research and limited or preliminary human data for cognitive effects. They are commonly used in nootropic protocols but lack the clinical validation of Tier 1 compounds.
BPC-157: Neuroprotection and Neurotransmitter Repair
BPC-157 is primarily known for tissue healing, but its neurological effects are increasingly studied. In animal models, BPC-157 counteracts dopaminergic and serotonergic system damage caused by various toxins and drugs.
Cognitive mechanism: BPC-157 influences the dopamine and serotonin systems, potentially repairing neurotransmitter imbalances that contribute to brain fog, poor motivation, and impaired executive function. In rat models, it protected against MPTP-induced dopaminergic neurotoxicity (a model for Parkinson's disease) and alcohol-induced brain damage (Sikiric et al. 2021, PMC8504390).
Cognitive applications: - Post-concussion cognitive recovery - Neurotransmitter balance restoration after substance use - Neuroprotection during periods of high oxidative stress
Dosage for cognitive use: 250-500 mcg/day subcutaneous, or 500 mcg oral (BPC-157 is one of few peptides with oral bioactivity). Cycles of 4-8 weeks.
Best for: Cognitive impairment from brain injury, substance-related neurotoxicity, neuroinflammation. Not a primary nootropic for healthy individuals seeking cognitive enhancement.
See our detailed guide on BPC-157 side effects for safety information.
Noopept (GVS-111): Memory Consolidation
Noopept is technically a dipeptide-derived small molecule (N-phenylacetyl-L-prolylglycine ethyl ester), not a traditional peptide. It is included here because it is consistently searched alongside nootropic peptides and its mechanism involves neurotrophic pathways.
Mechanism: Noopept increases BDNF and NGF expression in the hippocampus, enhancing long-term potentiation (LTP), the cellular basis of memory formation. It also modulates AMPA and NMDA glutamate receptors, improving signal transmission at excitatory synapses.
Human data: Limited. A small study in patients with mild cognitive disorders reported improvements in memory and attention, but large-scale RCTs are lacking. Most evidence comes from rodent behavioral studies showing enhanced spatial memory and fear conditioning.
Dosage: 10-30 mg orally or sublingually, 2-3 times daily. Cycles of 1.5-3 months. Onset of noticeable effects: 1-2 weeks (gradual, as BDNF accumulation takes time).
Best for: Memory consolidation, learning efficiency. Popular among students and professionals for sustained cognitive demands.
DSIP: Sleep-Dependent Cognitive Enhancement
Delta Sleep-Inducing Peptide (DSIP) enhances cognition indirectly by improving slow-wave sleep quality. Deep sleep is when memory consolidation occurs: hippocampal memories are transferred to neocortical long-term storage during delta wave activity.
Mechanism: DSIP promotes delta wave sleep without causing sedation during waking hours. A double-blind study in chronic insomnia patients showed improved sleep quality and architecture with DSIP administration (Schneider-Helmert & Schoenenberger 1983, PubMed 1299794).
Cognitive relevance: Poor sleep is the most common reversible cause of cognitive impairment. Improving sleep quality can produce dramatic improvements in memory, attention, and executive function. DSIP addresses the root cause rather than artificially stimulating cognition.
Dosage: 100-200 mcg subcutaneous injection, 30-60 minutes before bed. Cycles of 10-14 days.
Best for: Cognitive impairment caused by poor sleep, shift work, jetlag, or age-related sleep deterioration. Not a daytime nootropic.
Dihexa: The Retraction Problem
Dihexa deserves its own section because it is one of the most heavily marketed "cognitive peptides" online, and its evidence base has been fundamentally compromised.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University by Dr. Joseph Harding and colleagues. The foundational 2014 paper claimed Dihexa was "seven orders of magnitude more potent than BDNF" at promoting synaptogenesis through HGF/c-Met receptor activation (Benoist et al. 2014, originally in J Pharmacol Exp Ther).
What happened: This paper was retracted in April 2025 after investigation revealed image manipulation. Athira Pharma, the company founded to commercialize Dihexa-related compounds, paid a $4.07 million settlement in January 2025 to resolve allegations of data falsification involving Dr. Harding's research (Retraction Watch report).
What this means for users: - The "millions of times more potent than BDNF" claim has no verified foundation - Independent replication of the key synaptogenesis findings has not been published - Dihexa may still have biological activity (the compound exists and binds HGF), but the magnitude and specificity of its cognitive effects are unvalidated - Every vendor site and competitor article that repeats the potency claim is citing retracted data
Current status: Dihexa is still available from peptide vendors. Some users report subjective cognitive effects. Without the foundational study, these reports lack a validated mechanistic framework. The compound is not categorically ineffective, but the extraordinary claims that drove its popularity are not supported by reliable evidence.
Recommendation: Consider Semax, Selank, or Cerebrolysin as alternatives with intact evidence bases. If you choose to use Dihexa, understand that the primary published evidence for its cognitive effects has been retracted.
Tier 3: Preliminary Evidence (Preclinical Only)
These peptides show cognitive effects in animal models or in vitro studies. No controlled human cognitive data exists. They appear frequently on vendor sites listed alongside well-studied compounds, creating a misleading impression of equivalent evidence.
GHK-Cu: Neuroprotective Gene Modulation
GHK-Cu (copper peptide) is primarily known for skin and tissue repair. Recent research has explored intranasal delivery for neuroprotection. A 2023 study demonstrated that intranasal GHK-Cu modulated expression of genes involved in antioxidant defense and reduced neuroinflammatory markers in a mouse model (PMC10680828).
Cognitive applications remain speculative. GHK-Cu may protect neurons from age-related oxidative damage, but no study has measured cognitive outcomes in animals or humans following administration. For GHK-Cu dosage protocols, see our dedicated guide.
Epitalon: Circadian Rhythm and Indirect Cognitive Effects
Epitalon (Epithalon) is a tetrapeptide (Ala-Glu-Asp-Gly) that stimulates melatonin production from the pineal gland and activates telomerase. Its cognitive relevance is indirect: melatonin regulates circadian rhythm, and circadian disruption impairs cognition.
A 2025 comprehensive review covered Epitalon's effects on pineal function, telomere maintenance, and potential anti-aging applications (PMC11943447). No studies have directly measured cognitive outcomes from Epitalon use in humans.
Cognitive relevance: Strictly indirect. If circadian disruption is contributing to cognitive impairment, restoring melatonin production could help. For direct cognitive enhancement, Tier 1 peptides are more appropriate.
PE-22-28, P21, and FGL: Research-Stage Compounds
PE-22-28 is a spadin analogue that blocks TREK-1 potassium channels and upregulates BDNF expression. Animal studies show antidepressant-like effects comparable to fluoxetine, with onset within 4 days versus 3 weeks for SSRIs (PMC5601071). Cognitive effects have not been specifically measured. Available as intranasal research peptide. Very limited human use data.
P21 is a small peptide derived from Cerebrolysin that mimics the activity of ciliary neurotrophic factor (CNTF). In mouse models, intranasal P21 promoted hippocampal neurogenesis and improved spatial memory. It represents an attempt to isolate the active cognitive component of Cerebrolysin in a single, defined peptide. No human data exists.
FGL (FG Loop peptide) is derived from neural cell adhesion molecule (NCAM) and activates the FGFR receptor. In rodent models, FGL enhanced hippocampal-dependent memory formation and promoted synaptic plasticity through PKC pathway activation (Bhatt et al. 2004, PubMed 15115815). A 2018 review positioned FGL among the most promising peptide cognitive enhancers (Asua et al. 2018, PubMed 29030286). No human trials have been conducted.
These compounds are mentioned for completeness. They are actively researched but not ready for evidence-based cognitive enhancement protocols.
Cognitive Peptide Comparison: Choosing by Goal
Different cognitive goals call for different peptides. This table maps common cognitive complaints to the most evidence-supported peptide options.
| Cognitive Goal | Best Peptide | Alternative | Mechanism | Evidence Level |
|---|---|---|---|---|
| Sharper focus | Semax | Noopept | BDNF + dopamine | Strong |
| Better memory | Semax | Cerebrolysin | BDNF + synaptogenesis | Strong |
| Brain fog from anxiety | Selank | Semax + Selank stack | GABA + enkephalin | Strong |
| Brain fog from poor sleep | DSIP | Epitalon | Delta wave promotion | Moderate |
| Post-concussion recovery | BPC-157 | Cerebrolysin | Neuroprotection | Moderate |
| Age-related cognitive decline | Cerebrolysin | Semax | Neurotrophic factors | Strong |
| Neuroprotection | GHK-Cu | BPC-157 | Gene modulation | Preliminary |
| Neurotransmitter repair | BPC-157 | Selank | DA/5-HT system repair | Moderate |
| Learning speed | Noopept | Semax | LTP enhancement | Moderate |
The Semax + Selank stack is the most common cognitive peptide combination. Semax provides direct cognitive stimulation (focus, memory), while Selank removes anxiety-driven cognitive suppression. Both are intranasal, can be administered from separate spray bottles in the same session, and have complementary mechanisms without pharmacological overlap.
Common stacking protocols: - Morning: Semax 200-400 mcg intranasal + Selank 250-500 mcg intranasal - Afternoon: Semax 200 mcg intranasal (optional, if extended focus needed) - Duration: 10-14 day cycles with equal time off
Use our peptide interaction checker to verify compatibility before combining compounds. See the peptide stack calculator for dosing guidance.
Dosage Quick Reference
This table consolidates dosing information for the most commonly used cognitive peptides. All dosages represent commonly reported protocols from clinical practice and the research literature. None of these compounds are FDA-approved for cognitive enhancement in the United States.
| Peptide | Route | Typical Dose | Frequency | Cycle Length | Onset |
|---|---|---|---|---|---|
| Semax | Intranasal | 200-600 mcg/day | 2-3x daily | 10-14 days on, 10-14 off | 15-30 min |
| Selank | Intranasal | 250-500 mcg/day | 2-3x daily | 14-21 days | 15-30 min |
| Cerebrolysin | IV/IM | 5-30 mL/day | 1x daily | 20-28 days | 1-2 weeks |
| BPC-157 | SC or oral | 250-500 mcg/day | 1-2x daily | 4-8 weeks | 1-2 weeks |
| Noopept | Oral/sublingual | 10-30 mg/day | 2-3x daily | 6-12 weeks | 1-2 weeks |
| DSIP | SC injection | 100-200 mcg | 1x before bed | 10-14 days | Same night |
| GHK-Cu | Intranasal/SC | 200-600 mcg/day | 1-2x daily | 2-4 weeks | Unknown |
| PE-22-28 | Intranasal | 50-100 mcg/day | 1-2x daily | 10-14 days | 4-7 days (animal) |
For proper peptide preparation, use our reconstitution calculator. For storage guidance, see our how to store peptides guide.
Safety Considerations for Cognitive Peptides
Cognitive peptides as a class have favorable safety profiles in the available data. Semax and Selank have decades of clinical use in Russia with no serious adverse events in published literature. Cerebrolysin's safety is documented across multiple RCTs.
General risks: - Intranasal peptides (Semax, Selank): mild nasal irritation, occasional headache. No tolerance, dependence, or withdrawal effects reported. - Injectable peptides (BPC-157, DSIP): standard injection site reactions. See our injection guide for technique. - Noopept: occasional irritability at higher doses, headache. Generally well-tolerated at recommended doses.
Specific cautions: - Cerebrolysin: derived from porcine brain tissue. Contraindicated in individuals with epilepsy (may lower seizure threshold) or known allergy to porcine products. - BPC-157: avoid in active cancer (growth factor modulation). Monitor if on psychiatric medications (dopamine/serotonin interactions). - Dihexa: unknown safety profile due to retracted foundational research. Use at your own risk. - Stacking multiple cognitive peptides increases the theoretical risk of overstimulation or mood instability, though this has not been documented with Semax + Selank specifically.
Quality concerns: The peptide market lacks pharmaceutical regulation. Purchase from suppliers who provide third-party certificates of analysis (COA) with mass spectrometry data confirming identity and purity. This applies especially to Cerebrolysin (counterfeit products exist) and Dihexa (novel compound with limited production standards).
See our general guide on getting started with peptides for sourcing and quality verification advice.
Frequently Asked Questions
What is the best peptide for brain function?
Semax has the strongest evidence for direct cognitive enhancement in healthy individuals. It upregulates BDNF within 30 minutes of intranasal administration, improves focus and memory, and has been approved in Russia since 1994 for cognitive disorders. For anxiety-related brain fog, Selank is more appropriate. For age-related cognitive decline, Cerebrolysin has the strongest clinical trial data with proven effects in Alzheimer's patients.
What peptide clears brain fog?
The best peptide for brain fog depends on its cause. If brain fog stems from anxiety or chronic stress, Selank (250-500 mcg/day intranasal) is the first choice due to its GABA-modulating, anti-anxiety mechanism. If brain fog is from poor sleep, DSIP (100-200 mcg before bed) addresses the root cause. If brain fog follows a concussion or substance use, BPC-157 (250-500 mcg/day) supports neurotransmitter repair. For general cognitive dullness, Semax (200-600 mcg/day intranasal) provides broad nootropic effects.
Is Dihexa safe to use?
The safety profile of Dihexa is unknown. The foundational research paper (Benoist et al. 2014) was retracted in April 2025 for image manipulation, and Athira Pharma paid a $4.07 million settlement related to data falsification. Without validated research, the therapeutic window, long-term effects, and risk profile are all uncertain. Semax, Selank, and Cerebrolysin are better-characterized alternatives with established safety data.
Can you stack Semax and Selank together?
Yes. Semax and Selank are commonly stacked for cognitive enhancement. They work through complementary mechanisms: Semax upregulates BDNF and enhances focus, while Selank modulates GABA and reduces anxiety-driven cognitive impairment. Both are administered intranasally and can be used in the same session. A typical protocol is Semax 200-400 mcg + Selank 250-500 mcg, both intranasal, 2-3 times daily for 10-14 day cycles.
Do nootropic peptides cause tolerance or dependence?
Semax and Selank have shown no tolerance, dependence, or withdrawal effects in clinical studies, which distinguishes them from benzodiazepines, amphetamines, and other cognitive enhancers. Selank was specifically compared to medazepam (a benzodiazepine) in an anxiety trial and showed comparable efficacy without the dependence liability. Noopept has not shown tolerance in available studies. Cycling protocols (10-21 days on, equal time off) are recommended as a precaution.
What is the difference between Semax and Selank?
Semax is a stimulatory nootropic that enhances focus, memory, and mental energy through BDNF upregulation and dopamine modulation. Selank is a calming nootropic that improves cognition by reducing anxiety and stress through GABA and enkephalin modulation. Semax is better for tasks requiring concentration and learning speed. Selank is better for situations where anxiety impairs performance. Many users combine both for balanced cognitive enhancement.
Is Cerebrolysin available in the United States?
Cerebrolysin is not FDA-approved and is not commercially available in the United States. It is approved in over 40 countries (including Russia, China, and several European nations) for Alzheimer's disease, stroke, and traumatic brain injury. US-based individuals sometimes access it through international pharmacies or clinical trials. It requires IV or IM injection and medical supervision for the higher doses used in clinical studies.
How long do cognitive peptides take to work?
Intranasal peptides (Semax, Selank) produce noticeable effects within 15-30 minutes due to rapid nasal mucosal absorption. Noopept and BPC-157 typically require 1-2 weeks of consistent use before cognitive effects become apparent, as they work through gradual BDNF accumulation and neurotransmitter remodeling. DSIP improves sleep quality from the first dose. Cerebrolysin shows measurable cognitive improvement after 2-4 weeks of daily infusions in clinical studies.
The Bottom Line
The cognitive peptide landscape divides cleanly by evidence quality. Semax, Selank, and Cerebrolysin have human clinical data supporting their cognitive effects. BPC-157, Noopept, and DSIP have meaningful animal data and limited human evidence. Everything else is preclinical at best.
The most important takeaway: evidence quality varies enormously between compounds marketed identically. Semax has 30+ years of clinical use and regulatory approval. Dihexa had its key paper retracted. Both appear on the same vendor pages with the same "boosts cognition" framing. Distinguishing between them requires looking at the actual research, not marketing copy.
For most people seeking cognitive enhancement through peptides, the Semax + Selank intranasal stack represents the best risk-adjusted starting point. Both are well-characterized, self-administered, and have complementary mechanisms. For clinical-grade intervention in neurodegenerative conditions, Cerebrolysin under medical supervision has the strongest trial data.
Start with the peptide quiz for personalized recommendations, or explore our peptide profiles for detailed information on individual compounds including Semax, Selank, BPC-157, and DSIP.
Not Sure Which Peptide Protocol Is Right for You?
Take our 2-minute quiz for a personalized recommendation based on your goals and health profile.
Start the Quiz →